OV-90Homo sapiens (Human)Cancer cell line
Also known as: OV90, TOV-90
Quick Overview
OV-90 is a human ovarian cancer cell line derived from high-grade serous carcinoma, widely used in cancer research for studying...
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3768 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ascites[UBERON:UBERON_0007795] |
Donor Information
| Age | 64 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Adenocarcinoma of ovary |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | Serous Ovarian Cancer |
| OncoTree Code | SOC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000291_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Ser215Arg (c.643A>C) | Homozygous | - | from parent cell line OV-90 |
| MutationSimple | SMAD4 | p.Arg445Ter (c.1333C>T) | Homozygous | - | from parent cell line OV-90 |
| Gene fusion | CDKN2D | CDKN2D-WDFY2 | - | - | from parent cell line OV-90 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Velculescu V.E., Scharpf R.B.
Cell Rep. 25:2617-2633(2018).
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Cell Rep. 18:2343-2358(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Noonan A.M., Annunziata C.M.
Gynecol. Oncol. 142:332-340(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Helleman J.
PLoS ONE 9:E103988-E103988(2014).
CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
Milosavljevic A., Yen L.-S.
PLoS Genet. 10:E1004216-E1004216(2014).
Type-specific cell line models for type-specific ovarian cancer research.
Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
PLoS ONE 8:E72162-E72162(2013).
Evaluating cell lines as tumour models by comparison of genomic profiles.
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Nat. Commun. 4:2126.1-2126.10(2013).
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Lessey B.A., Jordan V.C., Bradford A.P.
Gynecol. Oncol. 127:241-248(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Genomic complexity and AKT dependence in serous ovarian cancer.";
Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Cancer Discov. 2:56-67(2012).
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin.
Sherman-Baust C.A., Becker K.G., Wood W.H. 3rd, Zhang Y.-Q., Morin P.J.
J. Ovarian Res. 4:21.1-21.11(2011).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Oncol. Rep. 23:1021-1026(2010).
Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.
Manderson E.N., Provencher D.M., Mes-Masson A.-M.
Oncogene 20:6617-6626(2001).